Tags

Type your tag names separated by a space and hit enter

Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.
Heart Fail Rev 2012; 17(2):221-8HF

Abstract

The prevalence of heart failure (HF) is increasing. A distinction is made between diastolic HF (preserved left ventricular ejection fraction (LVEF)) and systolic HF (reduced LVEF). Advanced glycation end-products (AGEs) are crystallized proteins that accumulate during ageing, but are particularly increased in patients with diabetes mellitus and in patients with renal failure. Through the formation of collagen crosslinks, and by interaction with the AGE-receptor, which impairs calcium handling and increases fibrosis, AGE-accumulation has pathophysiologically been associated with the development of diastolic and renal dysfunction. Interestingly, diastolic dysfunction is a frequent finding in elderly patients, diabetic patients and in patients with renal failure. Taken together, this suggests that AGEs are related to the development and progression of diastolic HF and renal failure. In this review, the role of AGEs as a possible pathophysiological factor that link the development and progression of heart and renal failure, is discussed. Finally, the role of AGE intervention as a possible treatment in HF patients will be discussed.

Authors+Show Affiliations

Department of Cardiology, University Medical Center Groningen, University of Groningen, 30.001, 9700, RB, Groningen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21259070

Citation

Willemsen, Suzan, et al. "Advanced Glycation End-products, a Pathophysiological Pathway in the Cardiorenal Syndrome." Heart Failure Reviews, vol. 17, no. 2, 2012, pp. 221-8.
Willemsen S, Hartog JW, Heiner-Fokkema MR, et al. Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail Rev. 2012;17(2):221-8.
Willemsen, S., Hartog, J. W., Heiner-Fokkema, M. R., van Veldhuisen, D. J., & Voors, A. A. (2012). Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Failure Reviews, 17(2), pp. 221-8. doi:10.1007/s10741-010-9225-z.
Willemsen S, et al. Advanced Glycation End-products, a Pathophysiological Pathway in the Cardiorenal Syndrome. Heart Fail Rev. 2012;17(2):221-8. PubMed PMID: 21259070.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. AU - Willemsen,Suzan, AU - Hartog,Jasper W L, AU - Heiner-Fokkema,M Rebecca, AU - van Veldhuisen,Dirk J, AU - Voors,Adriaan A, PY - 2011/1/25/entrez PY - 2011/1/25/pubmed PY - 2013/3/30/medline SP - 221 EP - 8 JF - Heart failure reviews JO - Heart Fail Rev VL - 17 IS - 2 N2 - The prevalence of heart failure (HF) is increasing. A distinction is made between diastolic HF (preserved left ventricular ejection fraction (LVEF)) and systolic HF (reduced LVEF). Advanced glycation end-products (AGEs) are crystallized proteins that accumulate during ageing, but are particularly increased in patients with diabetes mellitus and in patients with renal failure. Through the formation of collagen crosslinks, and by interaction with the AGE-receptor, which impairs calcium handling and increases fibrosis, AGE-accumulation has pathophysiologically been associated with the development of diastolic and renal dysfunction. Interestingly, diastolic dysfunction is a frequent finding in elderly patients, diabetic patients and in patients with renal failure. Taken together, this suggests that AGEs are related to the development and progression of diastolic HF and renal failure. In this review, the role of AGEs as a possible pathophysiological factor that link the development and progression of heart and renal failure, is discussed. Finally, the role of AGE intervention as a possible treatment in HF patients will be discussed. SN - 1573-7322 UR - https://www.unboundmedicine.com/medline/citation/21259070/full_citation L2 - https://doi.org/10.1007/s10741-010-9225-z DB - PRIME DP - Unbound Medicine ER -